Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more
Idorsia Ltd (IDRSF) - Total Assets
Latest total assets as of September 2025: $454.01 Million USD
Based on the latest financial reports, Idorsia Ltd (IDRSF) holds total assets worth $454.01 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Idorsia Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Idorsia Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Idorsia Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Idorsia Ltd's total assets of $454.01 Million consist of 50.5% current assets and 49.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.8% |
| Accounts Receivable | $65.41 Million | 12.9% |
| Inventory | $62.65 Million | 12.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $23.47 Million | 4.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Idorsia Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Idorsia Ltd's current assets represent 50.5% of total assets in 2024, a decrease from 82.3% in 2016.
- Cash Position: Cash and equivalents constituted 20.8% of total assets in 2024, down from 79.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 12.9% of total assets.
Idorsia Ltd Competitors by Total Assets
Key competitors of Idorsia Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Idorsia Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Idorsia Ltd generates 0.22x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Idorsia Ltd is currently not profitable relative to its asset base.
Idorsia Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.40 | 0.63 | 8.12 |
| Quick Ratio | 0.83 | 0.42 | 8.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $60.96 Million | $ -140.17 Million | $ 907.16 Million |
Idorsia Ltd - Advanced Valuation Insights
This section examines the relationship between Idorsia Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 28.08 |
| Latest Market Cap to Assets Ratio | 0.34 |
| Asset Growth Rate (YoY) | 1.2% |
| Total Assets | $505.89 Million |
| Market Capitalization | $171.80 Million USD |
Valuation Analysis
Below Book Valuation: The market values Idorsia Ltd's assets below their book value (0.34 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Idorsia Ltd's assets grew by 1.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Idorsia Ltd (2016–2024)
The table below shows the annual total assets of Idorsia Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $505.89 Million | +1.18% |
| 2023-12-31 | $500.00 Million | -44.70% |
| 2022-12-31 | $904.18 Million | -39.03% |
| 2021-12-31 | $1.48 Billion | +3.32% |
| 2020-12-31 | $1.44 Billion | +42.94% |
| 2019-12-31 | $1.00 Billion | -28.62% |
| 2018-12-31 | $1.41 Billion | +8.89% |
| 2017-12-31 | $1.29 Billion | +41.17% |
| 2016-12-31 | $915.12 Million | -- |